Open-label, Multicenter, Single Arm, Phase II Study Assessing Treatment Patient Preference for New Deferasirox Formulation (Film-coated Tablet) Compared to the Reference Deferasirox Dispersible Tablet Formulation
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Deferasirox (Primary)
- Indications Thalassaemia
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 11 Jul 2017 Planned End Date changed from 15 Apr 2020 to 15 Jul 2020.
- 11 Jul 2017 Planned primary completion date changed from 15 Apr 2020 to 15 Jul 2020.
- 11 Jul 2017 Status changed from not yet recruiting to recruiting.